Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Down 16.1% in April

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) was the target of a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 3,070,000 shares, a drop of 16.1% from the March 31st total of 3,660,000 shares. Based on an average trading volume of 400,200 shares, the days-to-cover ratio is presently 7.7 days. Currently, 8.9% of the company's shares are sold short.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the firm's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the sale, the insider now owns 202,721 shares of the company's stock, valued at $1,060,230.83. This trade represents a 5.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 22.50% of the stock is owned by corporate insiders.

Institutional Trading of Y-mAbs Therapeutics

A number of large investors have recently made changes to their positions in YMAB. Barclays PLC boosted its holdings in Y-mAbs Therapeutics by 433.4% in the third quarter. Barclays PLC now owns 69,222 shares of the company's stock worth $910,000 after purchasing an additional 56,244 shares during the last quarter. Principal Financial Group Inc. purchased a new position in shares of Y-mAbs Therapeutics in the 3rd quarter worth $267,000. JPMorgan Chase & Co. grew its holdings in shares of Y-mAbs Therapeutics by 10.4% in the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company's stock worth $399,000 after acquiring an additional 2,854 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Y-mAbs Therapeutics during the fourth quarter valued at $46,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Y-mAbs Therapeutics by 1.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company's stock valued at $2,228,000 after acquiring an additional 4,963 shares during the period. 70.85% of the stock is currently owned by institutional investors.

Y-mAbs Therapeutics Trading Down 9.2 %

YMAB stock traded down $0.39 during midday trading on Tuesday, hitting $3.86. The company's stock had a trading volume of 332,467 shares, compared to its average volume of 325,502. The company has a market cap of $174.77 million, a PE ratio of -7.15 and a beta of 0.53. The firm's 50-day moving average is $4.68 and its 200-day moving average is $7.68. Y-mAbs Therapeutics has a 12 month low of $3.84 and a 12 month high of $17.47.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. During the same period in the previous year, the company earned ($0.02) earnings per share. Analysts expect that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

Wall Street Analyst Weigh In

YMAB has been the subject of several research analyst reports. Morgan Stanley dropped their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research report on Wednesday, March 5th. Truist Financial lowered their target price on Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. Wedbush reissued an "outperform" rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Bank of America lowered shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price target for the company. in a research note on Tuesday, April 22nd. Finally, HC Wainwright cut their price objective on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Two equities research analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $17.40.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.